Moderna Rockets 93%, Merck Jumps 7% on Melanoma Therapy Success
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
modernamerck
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Moderna Inc. (MRNA) shares surged 93% and Merck & Co. (MRK) advanced 7% on August 19, 2026, after the companies announced their jointly developed melanoma therapy met its primary endpoint in a Phase 3 clinical trial. The monumental move for Moderna represents one of the largest single-session gains for a major biopharmaceutical company this decade, fundamentally repricing the stock based on the commercial prospects of its oncology pipeline. Merck's more modest gain reflects its larger market capitalization and diversified product portfolio beyond this single catalyst.
Phase 3 trial success represents the final regulatory hurdle before a drug can be submitted for approval to agencies like the U.S. Food and Drug Administration. Positive Phase 3 data often serves as the most significant value-inflection point for clinical-stage biotechnology companies, as it de-risks the asset and provides a clear line of sight to future revenue. For Moderna, a company whose valuation had been heavily tied to its COVID-19 vaccine revenue, this success demonstrates tangible progress in diversifying its platform into other therapeutic areas like oncology.
The last comparable single-day move for a large-cap biotech occurred on November 9, 2020, when Pfizer and BioNTech announced positive Phase 3 results for their COVID-19 vaccine, sending BioNTech shares up over 15%. Moderna's 93% surge is substantially larger, reflecting both the surprise element and the critical need for the company to validate its technology beyond mRNA vaccines for infectious diseases. The current macro backdrop of elevated interest rates has put particular pressure on pre-revenue biotech firms, making a positive data readout even more consequential for shareholder value.
Merck's involvement is strategic, leveraging its established oncology commercial infrastructure and expertise. The company has been actively building its immuno-oncology portfolio to complement its blockbuster drug Keytruda, which faces patent expiration later this decade. Success in melanoma provides a potential future combination therapy or successor product, a key pillar of Merck's long-term growth strategy as it prepares for the Keytruda revenue cliff.
Moderna's 93% appreciation is a historic move for a company of its scale. Prior to the announcement, Moderna's market capitalization was approximately $45 billion. A move of this magnitude adds over $40 billion in market value in a single session, a rarity for companies outside the cryptocurrency or speculative technology sectors. The stock had been trading near multi-year lows as investors questioned the sustainability of its COVID-related revenue.
Merck, as of 10:07 UTC today, trades at $152.55, representing a gain of 0.23% for the session, with a daily range between $148.59 and $154.49. While its 7% move on the announcement day was overshadowed by Moderna's surge, it still added over $20 billion to Merck's market capitalization due to its size. This demonstrates the asymmetric impact of a positive clinical readout on a partner's valuation; Moderna, as the smaller, more clinical-stage-focused company, experienced a much larger percentage gain.
The move starkly contrasts with the performance of the broader healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was largely unchanged on the day of the announcement, indicating the event was specific to these two companies rather than a sector-wide rally. Biotechnology ETFs like the iShares Biotechnology ETF (IBB) did see a lift, but gains were concentrated in a handful of names with direct exposure to oncology or mRNA technology, highlighting the targeted nature of the capital flows.
Volatility data further illustrates the event's significance. Moderna's options implied volatility had been elevated in the days leading up to the data readout, a common pattern before binary events. However, the magnitude of the move far exceeded the range priced into most options contracts, leading to significant losses for those selling volatility and massive gains for holders of out-of-the-money call options. This activity suggests a low level of market anticipation for such a decisively positive outcome.
The immediate market effect was a powerful rally in oncology-focused biotech stocks, particularly those with mRNA technology platforms or cancer immunotherapy assets in Phase 2 or Phase 3 development. Companies like BioNTech SE (BNTX) and CureVac N.V. (CVAC) saw sympathetic buying, though their gains were more muted, reflecting Moderna's unique position. Contract research organizations (CROs) that specialize in oncology trials also experienced positive momentum, as success reinforces demand for their services.
A counter-argument to the bullish sentiment is the remaining regulatory and commercial execution risk. FDA approval is not guaranteed, and even upon approval, commercial success depends on pricing, reimbursement, and adoption by oncologists. The therapy will also face competition from existing melanoma treatments. The market's reaction prices in a high probability of success, leaving the stock vulnerable to any setbacks during the regulatory review process or slower-than-expected commercial launch.
Positioning data indicates that the rally was likely fueled by short covering in Moderna and new long allocations from institutional healthcare funds that had been underweight the stock. Flow-of-funds analysis shows net buying across all time horizons, but the most aggressive buying came from quantitative funds reacting to the momentum signal and fundamental investors reassessing the company's pipeline value. For Merck, the buying was more subdued and likely originated from generalist investors seeking exposure to a positive catalyst in a large-cap pharmaceutical name.
The next specific catalyst is the formal presentation of the Phase 3 data at a major medical conference, such as the American Society of Clinical Oncology (ASCO) annual meeting. Detailed data on overall survival, progression-free survival, and side effect profiles will be scrutinized by clinicians and investors alike. The companies are also expected to submit the data to the FDA for regulatory review shortly thereafter; the acceptance of this submission will be a key milestone.
For Moderna, the $154.49 level represents a key technical resistance point to watch, as it was the session high. A sustained break above this level on continued volume would signal strong conviction behind the move. Investors will monitor the stock's ability to hold its gains in the coming weeks, as large single-day moves often see partial retracements as short-term traders take profits.
The companies' upcoming earnings calls will provide management commentary on the regulatory strategy and commercial preparation for the melanoma therapy. Merck's next quarterly call is scheduled for October 27, 2026, and Moderna's is scheduled for November 5, 2026. Guidance on manufacturing capacity, pricing considerations, and launch timelines will be critical for modeling future revenue impact. Success in this trial also raises questions about the potential for the therapy in other cancer indications, which would represent additional future catalysts.
A Phase 3 trial is the final stage of clinical testing before a company submits a drug for regulatory approval. The primary endpoint is the main result the trial is designed to measure, such as overall survival or progression-free survival. Meeting this endpoint means the drug demonstrated a statistically significant improvement over the control group, providing strong evidence of efficacy required for approval. It is the most important value-creating event in a drug's development lifecycle.
Modernas 93% single-day gain is exceptionally large for a company with a pre-announcement market capitalization near $45 billion. While smaller micro-cap biotech stocks can experience such moves on positive data, it is rare for a large-cap biopharma stock. For comparison, when BioNTech announced positive Phase 3 COVID-19 vaccine data in November 2020, its stock rose approximately 15%. The magnitude reflects both the surprise of the result and its importance for Moderna's strategic pivot beyond COVID-19 vaccines.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
